Amazentis, an innovative company in the field of combating aging as a disease and not as a simple human condition, has announced a publication in the journal Nature Metabolism in collaboration with researchers from the École Polytechnique Fédérale de Lausanne (EPFL) and the Swiss Institute of Bioinformatics (SIB) showing the safety and efficacy of Urolithin A in improving the health of cells and mitochondria.
After the first, extraordinary results of animal tests in 2016 (survival in some species increased by up to 45%) Urolitin A was administered orally in single and double daily doses for 4 weeks to 60 healthy elderly subjects in the scope of a double-blind experiment.
Roger Fielding, Professor of Medicine and Nutrition and Associate Director of the Jean Mayer Research Center at Tuft University commented: “Currently there were no effective solutions other than regular exercise to combat the decline in muscle functions. This is a first, important clinical validation that shows the promising role of Urolitin A in the management of muscle health as we age ”.
"Cellular and mitochondrial health declines with age: the discovery of a substance that can stop, manage or reverse this decline is a milestone in medicine," says Patrick Aebischer, co-author of the article.
"These positive results of Urolithin A show its potential in improving cellular health through mitophagy and biogenesis," adds Johan Auwerx, the other co-author.
Here the original article: https://www.businesswire.com/news/home/20190614005279/en/
